Imprimis Pharmaceuticals Price on March 8, 2018

If you're considering investing in Imprimis Stock, it is important to understand the factors that can impact its price. We have found zero technical indicators for Imprimis Pharmaceuticals, which you can use to evaluate the volatility of the firm.
  
Imprimis Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
IMMY
Based on monthly moving average Imprimis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imprimis Pharmaceuticals by adding Imprimis Pharmaceuticals to a well-diversified portfolio.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Price Boundaries

Imprimis Pharmaceuticals Period Price Range

Imprimis Pharmaceuticals April 25, 2024 Market Strength

Market strength indicators help investors to evaluate how Imprimis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Imprimis Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Imprimis Pharmaceuticals stock market strength indicators, traders can identify Imprimis Pharmaceuticals entry and exit signals to maximize returns
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Imprimis Stock

If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stocks Directory
Find actively traded stocks across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Fundamental Analysis
View fundamental data based on most recent published financial statements